One World Protected

The Gavi COVAX AMC 2021 Investment Opportunity Launch Event

15 April 2021 | 14:00 CET

 


 

View programme

Video stories

Gavi COVAX AMC – 2021 Investment Opportunity

Last updated on 15 April 2021

View full screen

DOWNLOAD: English | French | SpanishChineseArabicItalianGerman

About

On 15 April, Gavi and the United States government brought together world leaders, the private sector, civil society and key technical partners to galvanise resources and commitment to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC).

The One World Protected event launched the Investment Opportunity for the Gavi COVAX AMC, outlining the urgent need for its continued support and paving the way for a funding Summit in June.

Learn more

Hosts

 

José Manuel Barroso
Chair of the Gavi Board

 

 

Antony Blinken
Secretary of State, United States

 

 

Gloria Steele
USAID Acting Administrator

Key figures

Population >143 million pandemic-induced global new poor in 2021.
Economy US$ 9 trillion potential loss to the global economy if COVID-19 vaccines aren’t globally distributed.
Doses 1.8 billion doses of COVID-19 vaccine could be reserved through the Gavi COVAX AMC in 2021.
Economies 92 lower-income economies stand to benefit from COVID-19 vaccines provided through the Gavi COVAX AMC.
Funding ≥ US$ 2 billion is required by June 2021 to fully fund the Gavi COVAX AMC.

The Gavi COVAX Advance Market Commitment (AMC) is an innovative financial mechanism that ensures the world’s poorest countries will get access to COVID-19 vaccines, regardless of their ability to pay.

United States support for Gavi

In addition to committing US$ 4 billion over 2021 and 2022 to support Gavi’s COVID-19 related work, the U.S. is a long-standing supporter of Gavi. It was one of the Alliance’s original six donors and has contributed more than US$ 2.7 billion to our core work since 2000.

U.S. global health assistance has emphasised ending preventable child deaths through high-impact, low-cost interventions, and provision of vaccines and immunisations through Gavi is an important component of these efforts. Moreover, the United States continues to be a key partner to Gavi by coordinating programmatic objectives to ensure greater efficiency and impact on the ground.

Timeline of U.S. support for Gavi

  • 2000: One of the original six founding donors of Gavi
  • 2011: Pledges US$ 450 million at Gavi’s first replenishment 
  • 2015: Pledges US$ 1 billion to Gavi for 2015-2018 period
  • 2017: Announces US$ 20 million to support Gavi’s Ebola vaccine stockpile
  • 2020: Pledges US$ 1.16 billion to Gavi for the period 2020-2023
  • 2020: Provides US$ 4 billion for COVID-19 vaccine procurement and delivery, becoming Gavi’s largest donor
  • 2021: Hosts the One World Protected launch meeting (virtual event)

Gavi COVAX AMC donors

COVAX AMC donors table

Latest COVAX AMC news

We can stop the cycle of new variants continuing indefinitely with a pandemic vaccine pool

Without it we could face further delays in the global rollout and risk the gulf between the vaccine haves and have nots widening.

Breaking COVID's Grip

COVAX and the other international organizations committed to vaccine equity cannot end the COVID-19 pandemic without the continued support of governments, industry, and civil society. By working together, the world has a chance to tame the…

The impact of COVAX in Laos

Vaccination started off slow, but has steadily increased over 2021 thanks to public health messaging and vaccine deliveries.

12 Days of COVAX

All around the world, COVAX deliveries are helping to protect frontline health workers, reach nomadic communities, reunite families and allow schools to reopen. Since deliveries began in March, #VaccinesWork has been publishing snapshots that…

How the public came together to support COVID-19 vaccines for the world’s most vulnerable

People around the world have demonstrated global solidarity by donating to the COVAX Facility, providing vaccines to those who would otherwise have no access.

Last updated: 19 Jan 2022

Subscribe to our newsletter